GCGM
AVBP icon

General Catalyst Group Management’s ArriVent BioPharma AVBP Stock Holding History

General Catalyst Group Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.9M Hold
1,494,786
– – 27.55% 1
2026
Q1 		$34.5M Hold
1,494,786
– – 18.79% 2
2025
Q4 		$30.1M Hold
1,494,786
– – 13.56% 5
2025
Q3 		$27.6M Hold
1,494,786
– – 0.91% 5
2025
Q2 		$32.5M Hold
1,494,786
– – 0.76% 5
2025
Q1 		$27.6M Hold
1,494,786
– – 3.11% 6
2024
Q4 		$39.8M Hold
1,494,786
– – 3.49% 6
2024
Q3 		$35.1M Hold
1,494,786
– – 2.45% 6
2024
Q2 		$27.7M Hold
1,494,786
– – 2.39% 5
2024
Q1 		$26.7M Buy
+1,494,786
New +$30.1M 2.05% 7

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

General Catalyst Group Management's AVBP Position: Q2 2026 in Review

General Catalyst Group Management held its ArriVent BioPharma (AVBP) position steady in Q2 2026 at 1,494,786 shares worth $51.9M. The position accounts for 27.55% of the portfolio, ranked #1.

General Catalyst Group Management first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • General Catalyst Group Management held 1,494,786 shares of ArriVent BioPharma worth $51.9M as of Q2 2026.
  • General Catalyst Group Management left its ArriVent BioPharma share count unchanged in Q2 2026.
  • ArriVent BioPharma made up 27.55% of General Catalyst Group Management's portfolio in Q2 2026, its #1 holding.
  • General Catalyst Group Management first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on General Catalyst Group Management's 13F filing for Q2 2026, filed 17 Aug 2026.